A Massachusetts-based biotech company is finding early success on Tuesday after the company announced the Phase 3 DISSOLVE program of their SEL-212 in chronic refractory gout met...

To read the full story on AllPennyStocks.com, click here.

Selecta Biosciences (NASDAQ:SELB)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Selecta Biosciences Charts.
Selecta Biosciences (NASDAQ:SELB)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Selecta Biosciences Charts.